Cargando…

FGFR1 is an adverse outcome indicator for luminal A breast cancers

Fibroblast growth factor receptor 1 (FGFR1) has been suggested to be the candidate gene for 8p11–12 amplification in breast cancer and its therapeutic/prognostic value is explored. Most previous studies focused on FGFR1 gene amplification, which may not necessarily lead to protein expression. Theref...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yu-Jie, Tsang, Julia Y.S., Ni, Yun-Bi, Chan, Siu-Ki, Chan, Kui-Fat, Tse, Gary M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826266/
https://www.ncbi.nlm.nih.gov/pubmed/26673008
http://dx.doi.org/10.18632/oncotarget.6563
_version_ 1782426319875735552
author Shi, Yu-Jie
Tsang, Julia Y.S.
Ni, Yun-Bi
Chan, Siu-Ki
Chan, Kui-Fat
Tse, Gary M.
author_facet Shi, Yu-Jie
Tsang, Julia Y.S.
Ni, Yun-Bi
Chan, Siu-Ki
Chan, Kui-Fat
Tse, Gary M.
author_sort Shi, Yu-Jie
collection PubMed
description Fibroblast growth factor receptor 1 (FGFR1) has been suggested to be the candidate gene for 8p11–12 amplification in breast cancer and its therapeutic/prognostic value is explored. Most previous studies focused on FGFR1 gene amplification, which may not necessarily lead to protein expression. Therefore, analysis of protein level may have more clinical relevance. We evaluated FGFR1 expression in a large cohort of breast cancer by immunohistochemistry, correlated with the tumor clinic-pathologic features, biomarkers expression, and patient's survival. FGFR1 expression was associated mainly with luminal cancers, particularly luminal B subtype (23.5%; p < 0.001), and it also showed adverse prognostic impact on luminal A cancers. FGFR1 expression was associated with higher pN (p = 0.023), pT (p = 0.003) stages, lymphovascular invasion (p = 0.010), p-cadherin (p = 0.028), synaptophysin (p = 0.009) and SOX2 expression (p = 0.034) in luminal A cancers. FGFR1 expressing luminal A cancers showed a similar outcome as luminal B cancers. Multivariate Cox regression analysis demonstrated FGFR1 positive luminal A cancers to be an independently poor prognosticator for disease free survival in luminal cancers (hazard ratio = 3.341, p = 0.008). Thus FGFR1 could be useful in identifying the aggressive cases amongst heterogeneous luminal A cancers. Given the relevance of FGFR pathway in treatment resistance in luminal cancers, FGFR1 could be an important tumor biomarker and adverse prognostic factor potentially exploitable in the clinical management of luminal cancers.
format Online
Article
Text
id pubmed-4826266
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-48262662016-05-09 FGFR1 is an adverse outcome indicator for luminal A breast cancers Shi, Yu-Jie Tsang, Julia Y.S. Ni, Yun-Bi Chan, Siu-Ki Chan, Kui-Fat Tse, Gary M. Oncotarget Clinical Research Paper Fibroblast growth factor receptor 1 (FGFR1) has been suggested to be the candidate gene for 8p11–12 amplification in breast cancer and its therapeutic/prognostic value is explored. Most previous studies focused on FGFR1 gene amplification, which may not necessarily lead to protein expression. Therefore, analysis of protein level may have more clinical relevance. We evaluated FGFR1 expression in a large cohort of breast cancer by immunohistochemistry, correlated with the tumor clinic-pathologic features, biomarkers expression, and patient's survival. FGFR1 expression was associated mainly with luminal cancers, particularly luminal B subtype (23.5%; p < 0.001), and it also showed adverse prognostic impact on luminal A cancers. FGFR1 expression was associated with higher pN (p = 0.023), pT (p = 0.003) stages, lymphovascular invasion (p = 0.010), p-cadherin (p = 0.028), synaptophysin (p = 0.009) and SOX2 expression (p = 0.034) in luminal A cancers. FGFR1 expressing luminal A cancers showed a similar outcome as luminal B cancers. Multivariate Cox regression analysis demonstrated FGFR1 positive luminal A cancers to be an independently poor prognosticator for disease free survival in luminal cancers (hazard ratio = 3.341, p = 0.008). Thus FGFR1 could be useful in identifying the aggressive cases amongst heterogeneous luminal A cancers. Given the relevance of FGFR pathway in treatment resistance in luminal cancers, FGFR1 could be an important tumor biomarker and adverse prognostic factor potentially exploitable in the clinical management of luminal cancers. Impact Journals LLC 2015-12-11 /pmc/articles/PMC4826266/ /pubmed/26673008 http://dx.doi.org/10.18632/oncotarget.6563 Text en Copyright: © 2016 Shi et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Clinical Research Paper
Shi, Yu-Jie
Tsang, Julia Y.S.
Ni, Yun-Bi
Chan, Siu-Ki
Chan, Kui-Fat
Tse, Gary M.
FGFR1 is an adverse outcome indicator for luminal A breast cancers
title FGFR1 is an adverse outcome indicator for luminal A breast cancers
title_full FGFR1 is an adverse outcome indicator for luminal A breast cancers
title_fullStr FGFR1 is an adverse outcome indicator for luminal A breast cancers
title_full_unstemmed FGFR1 is an adverse outcome indicator for luminal A breast cancers
title_short FGFR1 is an adverse outcome indicator for luminal A breast cancers
title_sort fgfr1 is an adverse outcome indicator for luminal a breast cancers
topic Clinical Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826266/
https://www.ncbi.nlm.nih.gov/pubmed/26673008
http://dx.doi.org/10.18632/oncotarget.6563
work_keys_str_mv AT shiyujie fgfr1isanadverseoutcomeindicatorforluminalabreastcancers
AT tsangjuliays fgfr1isanadverseoutcomeindicatorforluminalabreastcancers
AT niyunbi fgfr1isanadverseoutcomeindicatorforluminalabreastcancers
AT chansiuki fgfr1isanadverseoutcomeindicatorforluminalabreastcancers
AT chankuifat fgfr1isanadverseoutcomeindicatorforluminalabreastcancers
AT tsegarym fgfr1isanadverseoutcomeindicatorforluminalabreastcancers